Mycophenolate Mofetil/ 生化试剂
简要描述:
*(Mycophenolate Mofetil/CAS 128794-94-5,MMF),又名*,是活体免疫999策略白菜手机论坛霉酚酸(MPA,CAS:24280-93-1)的酯类前药。MMF是一种非竞争性、选择性且可逆的次黄飘呤单核苷酸脱氢酶(IMPDH)999策略白菜手机论坛。
产品时间:2023-02-28
Mycophenolate Mofetil *
产品标签
Mycophenolic Acid (MPA) 霉酚酸;Immunosuppressive Drug 免疫999策略白菜手机论坛;Inosine monophosphatase dehydrogenase 次黄飘呤单核苷酸脱氢酶;IMPDH Inhibitor; Mycophenolate mofetil *;CAS NO:128794-94-5;
产品信息
产品名称 | 产品编号 | CAS NO. | 规格 | 价格(元) |
Mycophenolate Mofetil * | MZ9232-0100MG | 128794-94-5 | 100mg | 598 |
Mycophenolate Mofetil * | MZ9232-0500MG | 128794-94-5 | 500mg | 1788 |
Mycophenolate Mofetil * | MZ9232-1000MG | 128794-94-5 | 1g | 2698 |
产品描述
*(Mycophenolate Mofetil,MMF, CAS:128794-94-5),又名*,是活体免疫999策略白菜手机论坛霉酚酸(MPA,CAS:24280-93-1)的酯类前药。MMF是一种非竞争性、选择性且可逆的次黄飘呤单核苷酸脱氢酶(IMPDH)999策略白菜手机论坛,体外无细胞实验MMF对IMPDH I/II的IC50分别是39/27nM。淋巴细胞中对IMPDH的抑制,阻断GTP的从头合成并引起RNA和DNA合成的减少,从而防止淋巴细胞增殖和活化,并抑制抗体生成。这一免疫抑制活性使其在器官以植和自身免疫疾病(如狼疮)发挥积极作用。MMF能抑制I型胶原表达,改善MMP-1表达,并降低α-平滑肌肌动蛋白基因表达。
产品特性
1) CAS NO:128794-94-5
2) 化学名:6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4E-hexenoic acid, 2-(4-morpholinyl)ethyl ester
3) 同义名:MMF; RS61443; Linfonex; Cellcept®;
4) 分子式:C23H31NO7
5) 分子量:433.49
6) 纯度:≥98%
7) 外观:白色或类白色结晶性粉末
8) 溶解性:溶于甲醇,DMSO(20mg/ml),无水乙醇(1.4mg/ml),微溶于乙米,几乎不溶于水
9) 化学结构图:
注意事项
1) 本*(MMF)不是临床药物,只能用于科研用途,不能用于诊断或临床用途。
2) 为了您的安全和健康,请穿实验服并戴一次性手套操作。
使用方法【源自文献,仅作参考】
文献1,Nakanishi T et al. Effect of the inosine 5'-monophosphate dehydrogenase inhibitor BMS-566419 on rat cardiac allograft rejection. Int Immunopharmacol. 2010 Jan;10(1):91-7. PMID: 19840872 体内研究: 动物模型(Animal Model):Lewis rats with abdominal vascularized heterotopic cardiac transplantation 药物配制(Preparation):Mycophenolate mofetil (MMF) was suspended in 0.5% methylcellulose water. 注射剂量(Dosages):Beginning on the operation day, MMF (vehicle conrol, 5, 10, 15, 20 and 40mg/kg) were orally administered once daily for 14 consecutive days. After transplantation, cardiac allograft function was assessed by daily palpation for 28 days, and graft rejection was defined as the cessation of palpable cardiac graft beats. 给药途径(Administration):Oral (p.o.) |
文献2,von Vietinghoff S et al. Mycophenolate mofetil decreases atherosclerotic lesion size by depression of aortic T-lymphocyte and interleukin-17-mediated macrophage accumulation. J Am Coll Cardiol. 2011 May 24;57(21):2194-204. PMID: 21596236 体内研究: 动物模型(Animal Model):Young and aged Apoe−/− mice 注射剂量(Dosages):Mycophenolate as the prodrug mycophenolate mofetil was incorporated into high fat diet without cholate (405 of kcal from fat, 1.5% Cholesterol) to reach an oral dose of 30mg/kg body weight*day at a chow consumption of 0.1g/g body-weight. 给药途径(Administration):Oral (p.o.) |
相关产品
货号 | 名称 | 规格 |
MZ9231-0100MG | Mycophenolic Acid (MPA) 霉酚酸(麦可酚酸) | 100mg |
MZ9232-0100MG | Mycophenolate mofetil * | 100mg |
— —Written/Edited by V. Shallan【版权归MKBio懋康所有】
999策略白菜手机论坛是一家涉足于生命科学和生物技术领域研究的试剂、仪器和实验室消耗品与实验服务工作,主要从事细胞生物学、植物学、分子生物学、免疫学、生物化学、蛋白组学。生物制药与诊断试剂研发生产等领域。 本公司秉承“以人为本,以诚为信、合同守信"的经营理念。坚持"品质保障"的原则为广大客户提供优质产品。
Mycophenolate Mofetil/CAS 128794-94-5
Mycophenolate Mofetil/CAS 128794-94-5